{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:23:07Z","timestamp":1775272987190,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Public Health Research Foundation"},{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>To identify predictors of discontinuing treatment with teriparatide (TPTD) and alendronate (ALN), data from a randomized, controlled trial (JOINT-05) involving postmenopausal Japanese women at high risk of fracture were re-analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and Methods<\/jats:title>\n                <jats:p>Participants received sequential therapy with once-weekly TPTD for 72\u00a0weeks followed by ALN for 48\u00a0weeks (TPTD-ALN group) or monotherapy with ALN for 120\u00a0weeks (ALN group). Background data including comorbidities, fracture prevalence, cognitive function, quality of life, activities of daily living, bone metabolism parameters, and nutrient intake were collected. The endpoints were 3 types of discontinuations by the reason: a poor compliance, adverse events (AEs), or any reason including those unrelated to AEs or poor compliance. Odds ratios (ORs) of baseline predictors of discontinuation were evaluated by single or multiple regression analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 234 (49.0%) patients in the TPTD-ALN group and 167 (34.2%) patients in the ALN group discontinued. In the TPTD-ALN group, a lower serum calcium level was a significant predictor of compliance-related discontinuation. Serum 25-hydroxyvitamin D levels were lower in patients with lower serum calcium levels than with higher serum calcium levels. In the ALN group, poor cognitive function was significantly associated with compliance-related discontinuation, and higher body mass index and alcohol intake were predictors of AE-related discontinuation. Predictors of discontinuation were drug-specific. Lower serum calcium levels and poor cognitive function were predictors of discontinuing once-weekly TPTD and ALN, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>When starting TPTD and ALN treatment, careful attention to patients with lower serum calcium levels and poor cognitive function, respectively, may be needed for better treatment continuity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00774-024-01541-3","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T11:02:24Z","timestamp":1723633344000},"page":"675-680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictors of discontinuation of osteoporosis treatment: sub-analysis of the Japanese osteoporosis intervention trial-05 (JOINT-05)"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0847-5233","authenticated-orcid":false,"given":"Yasuhiro","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nakatsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hagino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Soen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"key":"1541_CR1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet 393:364\u2013376. https:\/\/doi.org\/10.1016\/S0140-6736(18)32112-3","journal-title":"Lancet"},{"key":"1541_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/bmb\/ldaa005","volume":"133","author":"MA Clynes","year":"2020","unstructured":"Clynes MA, Harvey NC, Curtis EM et al (2020) The epidemiology of osteoporosis. Br Med Bull 133:105\u2013117. https:\/\/doi.org\/10.1093\/bmb\/ldaa005","journal-title":"Br Med Bull"},{"key":"1541_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1586\/erp.10.76","volume":"10","author":"V Rabenda","year":"2010","unstructured":"Rabenda V, Reginster JY (2010) Overcoming problems with adherence to osteoporosis medication. Expert Rev Pharmacoecon Outcomes Res 10:677\u2013689. https:\/\/doi.org\/10.1586\/erp.10.76","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1541_CR4","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922\u2013928. https:\/\/doi.org\/10.1016\/j.bone.2005.10.022","journal-title":"Bone"},{"key":"1541_CR5","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s40520-022-02272-z","volume":"34","author":"N Fuggle","year":"2022","unstructured":"Fuggle N, Al-Daghri N, Bock O, Branco J, Bruy\u00e8re O et al (2022) Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clin Exp Res 34:2625\u20132634. https:\/\/doi.org\/10.1007\/s40520-022-02272-z","journal-title":"Aging Clin Exp Res"},{"key":"1541_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.849","volume":"5","author":"X Nogu\u00e9s","year":"2022","unstructured":"Nogu\u00e9s X, Carbonell MC, Canals L, Liz\u00e1n L, Palacios S (2022) Current situation of shared decision making in osteoporosis: a comprehensive literature review of patient decision aids and decision drivers. Health Sci Rep 5:e849. https:\/\/doi.org\/10.1002\/hsr2.849","journal-title":"Health Sci Rep"},{"key":"1541_CR7","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022. https:\/\/doi.org\/10.4065\/81.8.1013","journal-title":"Mayo Clin Proc"},{"key":"1541_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011470","volume":"97","author":"H Cho","year":"2018","unstructured":"Cho H, Byun JH, Song I, Kim HY, Ha YC, Kim TY, Lee YK, Jang S (2018) Effect of improved medication adherence on health care costs in osteoporosis patients. Medicine 97:e11470. https:\/\/doi.org\/10.1097\/MD.0000000000011470","journal-title":"Medicine"},{"key":"1541_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12877-019-1278-9","volume":"19","author":"SF Yu","year":"2019","unstructured":"Yu SF, Cheng JS, Chen YC, Chen JF, Hsu CY, Lai HM, Ko CH, Chiu WC, Su YJ, Cheng TT (2019) Adherence to anti-osteoporosis medication associated with lower mortality following hip fracture in older adults: a nationwide propensity score matched cohort study. BMC Geriatr 19:290. https:\/\/doi.org\/10.1186\/s12877-019-1278-9","journal-title":"BMC Geriatr"},{"key":"1541_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11914-006-0011-8","volume":"4","author":"DT Gold","year":"2006","unstructured":"Gold DT, Silverman S (2006) Review of adherence to medications for the treatment of osteoporosis. Curr Osteoporos Rep 4:21\u201327. https:\/\/doi.org\/10.1007\/s11914-006-0011-8","journal-title":"Curr Osteoporos Rep"},{"key":"1541_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00774-019-01051-7","volume":"38","author":"H Tsuchie","year":"2020","unstructured":"Tsuchie H, Miyakoshi N, Kasukawa Y, Abe H, Masutani N, Shimada Y (2020) Factors affecting continuation of weekly teriparatide administration in rural areas. J Bone Miner Metab 38:248\u2013253. https:\/\/doi.org\/10.1007\/s00774-019-01051-7","journal-title":"J Bone Miner Metab"},{"key":"1541_CR12","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00198-021-05996-2","volume":"32","author":"H Hagino","year":"2021","unstructured":"Hagino H, Sugimoto T, Tanaka S, Sasaki K, Sone T, Nakamura T, Soen S, Mori S (2021) A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese osteoporosis intervention trial-05. Osteoporos Int 32:2301\u20132311. https:\/\/doi.org\/10.1007\/s00198-021-05996-2","journal-title":"Osteoporos Int"},{"key":"1541_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00774-019-01074-0","volume":"38","author":"S Tanaka","year":"2020","unstructured":"Tanaka S, Mori S, Hagino H, Sugimoto T (2020) Design of a randomized trial of teriparatide followed by alendronate: Japanese osteoporosis intervention trial-05 (JOINT-05). J Bone Miner Metab 38:412\u2013417. https:\/\/doi.org\/10.1007\/s00774-019-01074-0","journal-title":"J Bone Miner Metab"},{"key":"1541_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"S Soen","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T, Japanese Society for Bone and Mineral Research and Japan Osteoporosis Society Joint Review Committee for the Revision of the Diagnostic Criteria for Primary Osteoporosis (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247\u2013257. https:\/\/doi.org\/10.1007\/s00774-013-0447-8","journal-title":"J Bone Miner Metab"},{"key":"1541_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148. https:\/\/doi.org\/10.1002\/jbmr.5650080915","journal-title":"J Bone Miner Res"},{"key":"1541_CR16","unstructured":"Mori E, Mitani Y, Yamadori A (1985) Usefulness of a Japanese version of the Mini-Mental State Test in neurological patients. Jpn J Neuropsychol 1: 82\u201390. (Japanese)"},{"key":"1541_CR17","unstructured":"EQ-5D: https:\/\/euroqol.org\/publications\/user-guides\/ Accessed 26 October 2023"},{"key":"1541_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3177\/jnsv.54.25","volume":"54","author":"K Uenishi","year":"2008","unstructured":"Uenishi K, Ishida H, Nakamura K (2008) Development of a simple food frequency questionnaire to estimate intakes of calcium and other nutrients for the prevention and management of osteoporosis. J Nutr Sci Vitaminol 54:25\u201329. https:\/\/doi.org\/10.3177\/jnsv.54.25","journal-title":"J Nutr Sci Vitaminol"},{"key":"1541_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1620\/tjem.2023.J022","volume":"260","author":"H Tsuchie","year":"2023","unstructured":"Tsuchie H, Abe H, Masutani N, Miyakoshi N (2023) Comparison of the continuation rate of twice-weekly and weekly teriparatide administration in a rural area. Tohoku J Exp Med 260:119\u2013126. https:\/\/doi.org\/10.1620\/tjem.2023.J022","journal-title":"Tohoku J Exp Med"},{"key":"1541_CR20","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s00774-022-01347-1","volume":"40","author":"R Fujita","year":"2022","unstructured":"Fujita R, Endo T, Takahata M, Haraya K, Suzuki H, Oda I, Kanayama M, Asano T, Shigenobu K, Iwata A, Yamada K, Takeuchi H, Ohura H, Yoneoka D, Iwasaki N (2022) Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis. J Bone Miner Metab 40:782\u2013789. https:\/\/doi.org\/10.1007\/s00774-022-01347-1","journal-title":"J Bone Miner Metab"},{"key":"1541_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275020","volume":"17","author":"YL Deng","year":"2022","unstructured":"Deng YL, Hsu CS, Hsu CY, Chen CH, Ou SF, Liu CF, Yang SH, Shih CH, Chen YM, Lee HT (2022) Predictors for self-discontinuation of anti-osteoporosis medication: a hospital-based real-world study. PLoS ONE 17:e0275020. https:\/\/doi.org\/10.1371\/journal.pone.0275020","journal-title":"PLoS ONE"},{"key":"1541_CR22","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4306\/pi.2009.6.3.180","volume":"6","author":"IS Ahn","year":"2009","unstructured":"Ahn IS, Kim JH, Kim S, Hung JW, Kim H, Kang HS, Kim DK (2009) Impairment of instrumental activities of daily living in patients with mild cognitive impairment. Psychiatry Investig 6:180\u2013184. https:\/\/doi.org\/10.4306\/pi.2009.6.3.180","journal-title":"Psychiatry Investig"},{"key":"1541_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2017.07.045","volume":"154","author":"JE Richter","year":"2018","unstructured":"Richter JE, Rubenstein JH (2018) Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology 154:267\u2013276. https:\/\/doi.org\/10.1053\/j.gastro.2017.07.045","journal-title":"Gastroenterology"},{"key":"1541_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/1759720X18785539","volume":"10","author":"A Jaleel","year":"2018","unstructured":"Jaleel A, Saag KG, Danila MI (2018) Improving drug adherence in osteoporosis: an update on more recent studies. Ther Adv Musculoskelet Dis 10:141\u2013149. https:\/\/doi.org\/10.1177\/1759720X18785539","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-024-01541-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-024-01541-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-024-01541-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T07:38:28Z","timestamp":1733902708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-024-01541-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1541"],"URL":"https:\/\/doi.org\/10.1007\/s00774-024-01541-3","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"21 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y Takeuchi has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mochida Pharma Co., Ltd., and Teijin Pharma Ltd. S Tanaka has received lecture fees from the Research Institute of Healthcare Data Science. He has received consultation fees and outsourcing fees from Eli Lilly and Company, Welby, Daiichi Sankyo Co., Ltd., Janssen Pharmaceutical K.K., Satt, and the Public Health Research Foundation. He has received research grants from the Japan Agency for Medical Research and Development, the Japanese Ministry of Health, Labour and Welfare, the Japanese Ministry of Education, Science and Technology, and Novo Nordisk. He engaged in a research project of the Japan Agency for Medical Research and Development. H Hagino received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Mochida Pharma Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. S Soen has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mochida Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. Y Nakatsuka, T Kuroda, and S Mori declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the Declaration of Helsinki and its amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}